What are the clinical implications of elevated cortisol in patients undergoing immunotherapy, and how should it be evaluated and managed?

Raised Cortisol During Immunotherapy: Clinical Implications and Management

Elevated cortisol in patients receiving immunotherapy requires immediate evaluation to distinguish between adrenal insufficiency requiring replacement therapy versus exogenous corticosteroid effects that may compromise treatment efficacy.

Critical Distinction: Endogenous vs. Exogenous Cortisol

The interpretation of "raised cortisol" fundamentally depends on whether you're measuring:

1. Low Cortisol (Adrenal Insufficiency) - An irAE Requiring Treatment

Primary or secondary adrenal insufficiency is a potentially life-threatening immune-related adverse event that demands prompt recognition and lifelong replacement therapy 1.

Diagnostic Workup:

• Morning ACTH (if >2-3× ULN suggests primary AI) and cortisol (if <3 mg/dL confirms AI)
• Basic metabolic panel focusing on hyponatremia, hyperkalemia
• Renin and aldosterone levels
• ACTH stimulation test if morning cortisol is 3-15 mg/dL (indeterminate range)
• Adrenal CT to exclude metastasis or hemorrhage 1

Management Algorithm by Grade 1:

• Grade 1 (Mild): Consider holding ICI until stabilized. Start hydrocortisone 15-20 mg daily in divided doses (2/3 morning, 1/3 early afternoon). Titrate up to maximum 30 mg daily if symptoms persist. Most primary AI requires fludrocortisone 0.05-0.1 mg daily.

• Grade 2 (Moderate): Consider holding ICI. Initiate stress-dose corticosteroids at 2-3× maintenance (hydrocortisone 30-50 mg or prednisone 20 mg daily) for acute symptoms. Add fludrocortisone. Taper to maintenance after 2 days.

• Grade 3-4 (Severe/Life-threatening): Hold ICI. Hospitalize for IV hydrocortisone 50-100 mg every 6-8 hours with at least 2L normal saline. Taper to oral maintenance over 5-7 days.

Critical Pitfall: Patients require lifelong replacement therapy, stress-dosing education, emergency injection training, and medical alert identification 1.

2. Exogenous Corticosteroids - Impact on Immunotherapy Efficacy

This is where the clinical dilemma becomes nuanced, with recent high-quality evidence providing clarity:

The most recent and highest quality evidence shows that corticosteroid peak dose—not cumulative dose—negatively impacts immunotherapy outcomes 2.

Key Findings from 2024 Pooled Analysis of Six Phase II/III Trials 2:

Among 834 patients receiving anti-PD-1 + anti-CTLA-4 therapy who required immunosuppression for treatment-related adverse events:

• High peak corticosteroid doses significantly worsened survival:

  • 1 mg/kg vs 0.5 mg/kg prednisolone: HR 1.15 for PFS, HR 1.21 for OS
  • 2 mg/kg vs 0.5 mg/kg: HR 1.43 for PFS, HR 1.66 for OS

• Cumulative corticosteroid dose showed no association with survival

• Second-line immunosuppressants showed no definitive impact (too few patients)

This fundamentally challenges traditional irAE management approaches that often default to high-dose corticosteroids.

Practical Management Algorithm

For irAE Management Requiring Corticosteroids:

Start with the lowest effective dose and shortest duration 3, 2:

1. Grade 2 irAEs: Consider starting at 0.5-1 mg/kg prednisone equivalent rather than reflexively using 1-2 mg/kg
2. Evaluate response at 72 hours and adjust accordingly 3
3. Taper over several weeks for grade 3 events 3
4. Consider early use of steroid-sparing agents (TNF-α inhibitors, vedolizumab, tocilizumab, mycophenolate) for severe or refractory cases rather than escalating corticosteroid doses 3

For Baseline Corticosteroid Use:

Baseline corticosteroid use (≥10 mg prednisone equivalent) for cancer-related symptoms is an independent negative prognostic factor 4:

• Associated with lower response rates, shorter PFS and OS
• Decreases circulating CX3CR1+CD8+ effector T cells
• Confounds interpretation of neutrophil-to-lymphocyte ratio and other blood-based biomarkers 4

However, corticosteroids given specifically for non-cancer indications (excluding palliative use) do not significantly impact immunotherapy efficacy 5, with pooled analysis showing OR 1.01 for response rate and HR 0.79 for OS.

Contradictory Evidence Reconciliation:

The apparent contradiction between studies 5, 4 resolves when recognizing that:

• Baseline steroids for palliative cancer symptoms indicate more aggressive disease biology (confounding by indication)
• Steroids for irAE management may not significantly impact outcomes when used appropriately 6
• Peak dose matters more than cumulative exposure 2

Monitoring Considerations

When corticosteroids are used during immunotherapy:

• Recognize that steroid-induced immunosuppression decreases circulating immune biomarkers, making them unreliable for treatment monitoring 4
• Lifestyle modifications to minimize corticosteroid adverse effects should be implemented 3
• Avoid long-acting steroids (dexamethasone) when possible; prefer hydrocortisone for physiologic replacement to recreate diurnal rhythm 1

Bottom Line

If evaluating truly elevated endogenous cortisol, you're likely missing the diagnosis—most immunotherapy endocrinopathies cause LOW cortisol (adrenal insufficiency). If managing exogenous corticosteroid use, prioritize the lowest peak dose that controls irAEs rather than focusing on cumulative exposure, as peak doses ≥1 mg/kg significantly worsen survival outcomes 2.